Literature DB >> 18333860

A review of the clinical pharmacology of maraviroc. Introduction.

Marta Boffito1, Samantha Abel.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18333860      PMCID： PMC2311405          DOI： 10.1111/j.1365-2125.2008.03131.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  13 in total

Review 1.  Current strategies in the treatment of HIV infection.

Authors:  O J Cohen; A S Fauci
Journal:  Adv Intern Med       Date:  2001

Review 2.  Co-receptor antagonists as HIV-1 entry inhibitors.

Authors:  Farida Shaheen; Ronald G Collman
Journal:  Curr Opin Infect Dis       Date:  2004-02       Impact factor: 4.915

Review 3.  Structured treatment interruption in patients infected with HIV: a new approach to therapy.

Authors:  Roy M Gulick
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.

Authors:  Jintanat Ananworanich; Angèle Gayet-Ageron; Michelle Le Braz; Wisit Prasithsirikul; Ploenchan Chetchotisakd; Sasisopin Kiertiburanakul; Warangkana Munsakul; Phitsanu Raksakulkarn; Somboon Tansuphasawasdikul; Sunee Sirivichayakul; Matthias Cavassini; Urs Karrer; Daniel Genné; Reto Nüesch; Pietro Vernazza; Enos Bernasconi; Dominic Leduc; Claudette Satchell; Sabine Yerly; Luc Perrin; Andrew Hill; Thomas Perneger; Praphan Phanuphak; Hansjakob Furrer; David Cooper; Kiat Ruxrungtham; Bernard Hirschel
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

5.  The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

Authors:  Y Huang; W A Paxton; S M Wolinsky; A U Neumann; L Zhang; T He; S Kang; D Ceradini; Z Jin; K Yazdanbakhsh; K Kunstman; D Erickson; E Dragon; N R Landau; J Phair; D D Ho; R A Koup
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

6.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

Authors:  G Dornadula; H Zhang; B VanUitert; J Stern; L Livornese; M J Ingerman; J Witek; R J Kedanis; J Natkin; J DeSimone; R J Pomerantz
Journal:  JAMA       Date:  1999-11-03       Impact factor: 56.272

7.  Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.

Authors:  M Samson; F Libert; B J Doranz; J Rucker; C Liesnard; C M Farber; S Saragosti; C Lapoumeroulie; J Cognaux; C Forceille; G Muyldermans; C Verhofstede; G Burtonboy; M Georges; T Imai; S Rana; Y Yi; R J Smyth; R G Collman; R W Doms; G Vassart; M Parmentier
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

Review 8.  The chemokine receptor, CCR5.

Authors:  Anja Mueller; Philip G Strange
Journal:  Int J Biochem Cell Biol       Date:  2004-01       Impact factor: 5.085

9.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

10.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728
View more
  3 in total

Review 1.  Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

Authors:  Michelle A Rudek; Charles Flexner; Richard F Ambinder
Journal:  Lancet Oncol       Date:  2011-05-12       Impact factor: 41.316

Review 2.  Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.

Authors:  Caroline M Perry
Journal:  Drugs       Date:  2010-06-18       Impact factor: 9.546

3.  Cytochrome P450 3A5 plays a prominent role in the oxidative metabolism of the anti-human immunodeficiency virus drug maraviroc.

Authors:  Yanhui Lu; Craig W Hendrix; Namandjé N Bumpus
Journal:  Drug Metab Dispos       Date:  2012-08-24       Impact factor: 3.922
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.